The report is titled as ‘Liquid Biopsy Market: Opportunity Analysis and Future Assessment 2020-2028’. An overview of conceptual frameworks, analytical approaches of the liquid biopsy market is the main objective of the report, which further consists the market opportunity and insights of the data involved in the making of the respective market. liquid biopsy market is expected to grow with significant rate in the near future.
The global liquid biopsy market in 2020 is estimated for more than US$ 1,013.6 Mn and expected to reach a value of US$ 2,563.9 Mn by 2028 with a significant CAGR of 12.3%.
Liquid Biopsy Market Definition
The liquid biopsy is a largely non-invasive clinical test performed in order to identify the cancer cells from the tumor that are flowing in the blood or in the DNA from tumor cells that are mixed in blood. The liquid biopsy is a medical procedure performed on the sample of blood of a patient, in order to diagnose cancer at an initial stage or it may help in monitoring the efficiency of the treatment provided to the patients as well as in planning the further treatment.
Also, if the liquid biopsy procedure is performed multiple times by regularly taking blood samples over time, it is also likely to assist the healthcare professionals to monitor the molecular changes taking place in the tumor of the patient.
Owing to all such factors, the liquid biopsy considerably has numerous benefits which elevates its demand all across the world. Attributing to which, the global liquid biopsy market is projected to witness significant growth in the forthcoming years.
Liquid Biopsy Market Dynamics
The growing prevalence of cancer among the population is one of the major aspects that is projected to boost the growth of the global liquid biopsy market in the near future. For example, In 2018, around 18.1 million new cases and 9.6 million fatalities were recorded due to cancer globally, as per the World Health Organization.
In addition, the liquid biopsy is the medical procedure with a massive number of benefits, which is why it is preferred excessively, thereby fueling the growth of the global liquid biopsy market. One of the most beneficial aspect of the liquid biopsy is that it is a non-invasive procedure and thus, it prevent the painful extraction of the sample of tissues and therefore eradicate the pain affiliated with the process, which in turn is expected to further accelerate the growth of the global liquid biopsy market in the upcoming future.
By the same token, there is a substantial number of favorable trials of liquid biopsy owing to the constant advancements, which is also acting as a positive factor in order to further augment the growth of the global liquid biopsy market during the forecast timeframe.
However, the constant research and development activities has resulted in other alternatives for liquid biopsy, which may hold back the growth of the global liquid biopsy market in the coming years.
Liquid Biopsy Market Key Players
Some of the key participating players in the liquid biopsy market are Biocept, Inc., Qiagen N.V., Roche Diagnostics, Bio-Rad Laboratories, Inc., Myriad Genetics, Inc., Menarini-Silicon Biosystems, Trovagene, Inc., Guardant Health, Inc., Mdxhealth SA, Genomic Health, Inc., Raindance Technologies, Inc., Thermo Fisher Scientific Inc., and Illumina, Inc.
Liquid Biopsy Market Segmentation
The liquid biopsy market is segmented on the basis of circulating biomarker, cancer type, end user, product type, and by region.
On the basis of circulating biomarker, the global liquid biopsy market is segmented into
• Circulating Tumor Cells
• Circulating Tumor DNA (CTDNA)
• Cell-Free DNA
• Extracellular Vesicles (Evs)
• Other Circulating Biomarkers
While on the basis of cancer type the market can be segmented into
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Liver Cancer
• Other Cancers
On the basis of Clinical Application the market can be segmented into
• Early Cancer Screening
• Therapy Selection
• Treatment Monitoring
• Recurrence Monitoring
On the basis of Product the market is segmented into
• Assay Kits
• Instruments
On the basis of End User the market is segmented into
• Reference Laboratories
• Hospitals and Physician Laboratories
• Academic and Research Centers
• Other
On the basis of Region, the global liquid biopsy market is segmented into
• North America (U.S., Canada)
• Latin America (Brazil, Mexico, Argentina, Rest of Latin America)
• Europe (U.K., Germany, Italy, France, Spain, Russia, Poland, BENELUX, NORDIC)
• Asia Pacific (China, India, Japan, Australia and New Zealand, South Korea, ASEAN, Rest of Asia)
• Middle East (GCC Countries, Israel, Oman, Rest of Middle East)
• Africa (South Africa, Egypt, North Africa, Rest of Africa)
MMC Overview on Liquid Biopsy Market Report
The non-identical approach of Meridian Market Consultants stands with conceptual methods backed up with the data analysis. The novel market understanding approach makes up the standard of the assessment results that give better opportunity for the customers to put their effort.
A research report on the Liquid Biopsy market by Meridian Market Consultants is an in-depth and extensive study of the market based on the necessary data crunching and statistical analysis. It provides a brief view of the dynamics flowing through the market, which includes the factors that supports market and the factors that are acting as impedance for the growth of the market.
Furthermore, the report includes the various trends and opportunities in the respective market in different regions for a better understanding of readers that helps to analyze the potential of the market.
Factors that are benchmarked while estimating the market
Various factors that are benchmarked while estimating the market growth includes (but not restricted to):
• New product designs and launches
• Current product compliance
• Reimbursement
• Concerns for use of Liquid Biopsy
• Advantages of Liquid Biopsy
Actions taken by the manufacturer and respective regulatory authorities also impact the market growth of the segment. These factors are understood at regional level and in major countries globally for providing regional insights of the product segment in the report. This helps our clients to take informed decision.
A mix of top-down and bottom-up approach is followed to arrive and validate our market value estimations. For a product segment like wherein one/two manufacturer(s) dominates the market, it’s products sales, previous growth rates and market expansion plans are considered to generate market share in the global market.
1. Global Liquid Biopsy Market Report Overview
1.1. Introduction
1.2. Report Description
1.3. Methodology
2. Global Liquid Biopsy Market Overview
2.1. Introduction
2.1.1. Market Definition
2.1.2. Market Taxonomy
2.2. Executive Summary
2.3. Global Liquid Biopsy Market Snapshot
2.4. Global Liquid Biopsy Market Size and Forecast, 2020–2028
2.4.1. Introduction
2.4.2. Market Value Forecast and Annual Growth Rate (AGR) Comparison (2020–2028)
2.5. Global Liquid Biopsy Market Dynamics
2.5.1. Drivers
2.5.2. Restraints
2.5.3. Opportunity
2.5.4. Trends
2.6. Key Regulations
2.7. Porter’s Five Forces Model
3. Global Liquid Biopsy Market, By Product type
3.1. Introduction
3.1.1. Annual Growth Rate Comparison, By Product type
3.1.2. BPS Analysis, By Product type
3.2. Market Revenue (US$Mn) Forecast, By Product type
3.2.1. Assay Kits
3.2.2. Instruments
3.3. Global Liquid Biopsy Market Attractiveness Index, By Product type
4. Global Liquid Biopsy Market, By Circulating Biomarker
4.1. Introduction
4.1.1. Annual Growth Rate Comparison, By Circulating Biomarker
4.1.2. BPS Analysis, By Circulating Biomarker
4.2. Market Revenue (US$Mn) Forecast, By Circulating Biomarker
4.2.1. Circulating Tumor Cells
4.2.2. Circulating Tumor DNA (CTDNA)
4.2.3. Cell-Free DNA
4.2.4. Extracellular Vesicles (Evs)
4.2.5. Other Circulating Biomarkers
4.3. Global Liquid Biopsy Market Attractiveness Index, By Circulating Biomarker
5. Global Liquid Biopsy Market, By Cancer Type
5.1. Introduction
5.1.1. Annual Growth Rate Comparison, By Cancer Type
5.1.2. BPS Analysis, By Cancer Type
5.2. Market Revenue (US$Mn) Forecast, By Cancer Type
5.2.1. Lung Cancer
5.2.2. Breast Cancer
5.2.3. Colorectal Cancer
5.2.4. Prostate Cancer
5.2.5. Liver Cancer
5.2.6. Other Cancers
5.3. Global Liquid Biopsy Market Attractiveness Index, By Cancer Type
6. Global Liquid Biopsy Market, By Clinical Application
6.1. Introduction
6.1.1. Annual Growth Rate Comparison, By Clinical Application
6.1.2. BPS Analysis, By Clinical Application
6.2. Market Revenue (US$Mn) Forecast, By Clinical Application
6.2.1. Early Cancer Screening
6.2.2. Therapy Selection
6.2.3. Treatment Monitoring
6.2.4. Recurrence Monitoring
6.3. Global Liquid Biopsy Market Attractiveness Index, By Clinical Application
7. Global Liquid Biopsy Market, By End User
7.1. Introduction
7.1.1. Annual Growth Rate Comparison, By End User
7.1.2. BPS Analysis, By End User
7.2. Market Revenue (US$Mn) Forecast, By End User
7.2.1. Reference Laboratories
7.2.2. Hospitals and Physician Laboratories
7.2.3. Academic and Research Centers
7.2.4. Other
7.3. Global Liquid Biopsy Market Attractiveness Index, By End User
8. Global Liquid Biopsy Market, By Region
8.1. Introduction
8.1.1. Annual Growth Rate Comparison, By Region
8.1.2. BPS Analysis, By Region
8.2. Market Revenue (US$Mn) Forecast, By Region
8.2.1. North America
8.2.2. Latin America
8.2.3. Europe
8.2.4. Asia Pacific
8.2.5. Middle East
8.2.6. Africa
8.3. Global Liquid Biopsy Market Attractiveness Index, By Region
9. North America Liquid Biopsy Market Analysis and Forecast, 2020–2028
9.1. Introduction
9.1.1. Annual Growth Rate Comparison, By Country
9.1.2. BPS Analysis, By Country
9.2. Market Revenue (US$Mn) Forecast, By Country
9.2.1. U.S. Liquid Biopsy Market
9.2.2. Canada Liquid Biopsy Market
9.3. North America Liquid Biopsy Market, By Product type
9.3.1. Assay Kits
9.3.2. Instruments
9.4. North America Liquid Biopsy Market, By Circulating Biomarker
9.4.1. Circulating Tumor Cells
9.4.2. Circulating Tumor DNA (CTDNA)
9.4.3. Cell-Free DNA
9.4.4. Extracellular Vesicles (Evs)
9.4.5. Other Circulating Biomarkers
9.5. North America Liquid Biopsy Market, By Cancer Type
9.5.1. Lung Cancer
9.5.2. Breast Cancer
9.5.3. Colorectal Cancer
9.5.4. Prostate Cancer
9.5.5. Liver Cancer
9.5.6. Other Cancers
9.6. North America Liquid Biopsy Market, By Clinical Application
9.6.1. Early Cancer Screening
9.6.2. Therapy Selection
9.6.3. Treatment Monitoring
9.6.4. Recurrence Monitoring
9.7. North America Liquid Biopsy Market, By End User
9.7.1. Reference Laboratories
9.7.2. Hospitals and Physician Laboratories
9.7.3. Academic and Research Centers
9.7.4. Other
9.8. North America Liquid Biopsy Market Attractiveness Index
9.8.1. By Country
9.8.2. By Product type
9.8.3. By Circulating Biomarker
9.8.4. By Cancer Type
9.8.5. By End User
10. Latin America Liquid Biopsy Market Analysis and Forecast, 2020–2028
10.1. Introduction
10.1.1. Annual Growth Rate Comparison, By Country
10.1.2. BPS Analysis, By Country
10.2. Market (US$Mn) Forecast, By Country
10.2.1. Brazil Liquid Biopsy Market
10.2.2. Mexico Liquid Biopsy Market
10.2.3. Argentina Liquid Biopsy Market
10.2.4. Rest of Latin America Liquid Biopsy Market
10.3. Latin America Liquid Biopsy Market, By Product type
10.3.1. Assay Kits
10.3.2. Instruments
10.4. Latin America Liquid Biopsy Market, By Circulating Biomarker
10.4.1. Circulating Tumor Cells
10.4.2. Circulating Tumor DNA (CTDNA)
10.4.3. Cell-Free DNA
10.4.4. Extracellular Vesicles (Evs)
10.4.5. Other Circulating Biomarkers
10.5. Latin America Liquid Biopsy Market, By Cancer Type
10.5.1. Lung Cancer
10.5.2. Breast Cancer
10.5.3. Colorectal Cancer
10.5.4. Prostate Cancer
10.5.5. Liver Cancer
10.5.6. Other Cancers
10.6. Latin America Liquid Biopsy Market, By Clinical Application
10.6.1. Early Cancer Screening
10.6.2. Therapy Selection
10.6.3. Treatment Monitoring
10.6.4. Recurrence Monitoring
10.7. Latin America Liquid Biopsy Market, By End User
10.7.1. Reference Laboratories
10.7.2. Hospitals and Physician Laboratories
10.7.3. Academic and Research Centers
10.7.4. Other
10.8. Latin America Liquid Biopsy Market Attractiveness Index
10.8.1. By Country
10.8.2. By Product type
10.8.3. By Circulating Biomarker
10.8.4. By Cancer Type
10.8.5. By End User
11. Europe Liquid Biopsy Market Analysis and Forecast, 2020–2028
11.1. Introduction
11.1.1. Annual Growth Rate Comparison, By Country
11.1.2. BPS Analysis, By Country
11.2. Market (US$Mn) Forecast, By Country
11.2.1. U.K. Liquid Biopsy Market
11.2.2. Germany Liquid Biopsy Market
11.2.3. Italy Liquid Biopsy Market
11.2.4. France Liquid Biopsy Market
11.2.5. Spain Liquid Biopsy Market
11.2.6. Russia Liquid Biopsy Market
11.2.7. Poland Liquid Biopsy Market
11.2.8. BENELUX Liquid Biopsy Market
11.2.9. NORDIC Liquid Biopsy Market
11.2.10. Rest of Europe Liquid Biopsy Market
11.3. Europe Liquid Biopsy Market, By Product type
11.3.1. Assay Kits
11.3.2. Instruments
11.4. Europe Liquid Biopsy Market, By Circulating Biomarker
11.4.1. Circulating Tumor Cells
11.4.2. Circulating Tumor DNA (CTDNA)
11.4.3. Cell-Free DNA
11.4.4. Extracellular Vesicles (Evs)
11.4.5. Other Circulating Biomarkers
11.5. Europe Liquid Biopsy Market, By Cancer Type
11.5.1. Lung Cancer
11.5.2. Breast Cancer
11.5.3. Colorectal Cancer
11.5.4. Prostate Cancer
11.5.5. Liver Cancer
11.5.6. Other Cancers
11.6. Europe Liquid Biopsy Market, By Clinical Application
11.6.1. Early Cancer Screening
11.6.2. Therapy Selection
11.6.3. Treatment Monitoring
11.6.4. Recurrence Monitoring
11.7. Europe Liquid Biopsy Market, By End User
11.7.1. Reference Laboratories
11.7.2. Hospitals and Physician Laboratories
11.7.3. Academic and Research Centers
11.7.4. Other
11.8. Europe Liquid Biopsy Market Attractiveness Index
11.8.1. By Country
11.8.2. By Product type
11.8.3. By Circulating Biomarker
11.8.4. By Cancer Type
11.8.5. By End User
12. Asia Pacific Liquid Biopsy Market Analysis and Forecast, 2020–2028
12.1. Introduction
12.1.1. Annual Growth Rate Comparison, By Country
12.1.2. BPS Analysis, By Country
12.2. Market (US$Mn) Forecast, By Country
12.2.1. China Liquid Biopsy Market
12.2.2. India Liquid Biopsy Market
12.2.3. Japan Liquid Biopsy Market
12.2.4. Australia and New Zealand Liquid Biopsy Market
12.2.5. South Korea Liquid Biopsy Market
12.2.6. ASEAN Liquid Biopsy Market
12.2.7. Rest of Asia Pacific Liquid Biopsy Market
12.3. Asia Pacific Liquid Biopsy Market, By Product type
12.3.1. Assay Kits
12.3.2. Instruments
12.4. Asia Pacific Liquid Biopsy Market, By Circulating Biomarker
12.4.1. Circulating Tumor Cells
12.4.2. Circulating Tumor DNA (CTDNA)
12.4.3. Cell-Free DNA
12.4.4. Extracellular Vesicles (Evs)
12.4.5. Other Circulating Biomarkers
12.5. Asia Pacific Liquid Biopsy Market, By Cancer Type
12.5.1. Lung Cancer
12.5.2. Breast Cancer
12.5.3. Colorectal Cancer
12.5.4. Prostate Cancer
12.5.5. Liver Cancer
12.5.6. Other Cancers
12.6. Asia Pacific Liquid Biopsy Market, By Clinical Application
12.6.1. Early Cancer Screening
12.6.2. Therapy Selection
12.6.3. Treatment Monitoring
12.6.4. Recurrence Monitoring
12.7. Asia Pacific Liquid Biopsy Market, By End User
12.7.1. Reference Laboratories
12.7.2. Hospitals and Physician Laboratories
12.7.3. Academic and Research Centers
12.7.4. Other
12.8. Asia Pacific Liquid Biopsy Market Attractiveness Index
12.8.1. By Country
12.8.2. By Product type
12.8.3. By Circulating Biomarker
12.8.4. By Cancer Type
12.8.5. By End User
13. Middle East Liquid Biopsy Market, By Region
13.1. Introduction
13.1.1. Annual Growth Rate Comparison, By Country
13.1.2. BPS Analysis, By Country
13.2. Market (US$Mn) Forecast, By Country
13.2.1. GCC Countries Liquid Biopsy Market
13.2.2. Israel Liquid Biopsy Market
13.2.3. Oman Liquid Biopsy Market
13.2.4. Rest of Middle East Liquid Biopsy Market
13.3. Middle East Liquid Biopsy Market, By Product type
13.3.1. Assay Kits
13.3.2. Instruments
13.4. Middle East Liquid Biopsy Market, By Circulating Biomarker
13.4.1. Circulating Tumor Cells
13.4.2. Circulating Tumor DNA (CTDNA)
13.4.3. Cell-Free DNA
13.4.4. Extracellular Vesicles (Evs)
13.4.5. Other Circulating Biomarkers
13.5. Middle East Liquid Biopsy Market, By Cancer Type
13.5.1. Lung Cancer
13.5.2. Breast Cancer
13.5.3. Colorectal Cancer
13.5.4. Prostate Cancer
13.5.5. Liver Cancer
13.5.6. Other Cancers
13.6. Middle East Liquid Biopsy Market, By Clinical Application
13.6.1. Early Cancer Screening
13.6.2. Therapy Selection
13.6.3. Treatment Monitoring
13.6.4. Recurrence Monitoring
13.7. Middle East Liquid Biopsy Market, By End User
13.7.1. Reference Laboratories
13.7.2. Hospitals and Physician Laboratories
13.7.3. Academic and Research Centers
13.7.4. Other
13.8. Middle East Liquid Biopsy Market Attractiveness Index
13.8.1. By Country
13.8.2. By Product type
13.8.3. By Circulating Biomarker
13.8.4. By Cancer Type
13.8.5. By End User
14. Africa Liquid Biopsy Market, By Region
14.1. Introduction
14.1.1. Annual Growth Rate Comparison, By Country
14.1.2. BPS Analysis, By Country
14.2. Market (US$Mn) Forecast, By Country
14.2.1. South Africa Liquid Biopsy Market
14.2.2. Egypt Liquid Biopsy Market
14.2.3. North Africa Liquid Biopsy Market
14.2.4. Rest of Africa Liquid Biopsy Market
14.3. Africa Liquid Biopsy Market, By Product type
14.3.1. Assay Kits
14.3.2. Instruments
14.4. Africa Liquid Biopsy Market, By Circulating Biomarker
14.4.1. Circulating Tumor Cells
14.4.2. Circulating Tumor DNA (CTDNA)
14.4.3. Cell-Free DNA
14.4.4. Extracellular Vesicles (Evs)
14.4.5. Other Circulating Biomarkers
14.5. Africa Liquid Biopsy Market, By Cancer Type
14.5.1. Lung Cancer
14.5.2. Breast Cancer
14.5.3. Colorectal Cancer
14.5.4. Prostate Cancer
14.5.5. Liver Cancer
14.5.6. Other Cancers
14.6. Africa Liquid Biopsy Market, By Clinical Application
14.6.1. Early Cancer Screening
14.6.2. Therapy Selection
14.6.3. Treatment Monitoring
14.6.4. Recurrence Monitoring
14.7. Africa Liquid Biopsy Market, By End User
14.7.1. Reference Laboratories
14.7.2. Hospitals and Physician Laboratories
14.7.3. Academic and Research Centers
14.7.4. Other
14.8. Africa Liquid Biopsy Market Attractiveness Index
14.8.1. By Country
14.8.2. By Product type
14.8.3. By Circulating Biomarker
14.8.4. By Cancer Type
14.8.5. By End User
15. Recommendation
15.1. Market Strategy
16. Competitive Landscape
16.1. Competition Dashboard
16.2. List and Company Overview of Global Key Players
16.3. Company Profiles
16.3.1. Biocept, Inc.
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Key Developments
16.3.1.5. Business Strategies
16.3.2. Qiagen N.V.
16.3.3. Roche Diagnostics
16.3.4. Bio-Rad Laboratories, Inc.
16.3.5. Myriad Genetics, Inc.
16.3.6. Menarini-Silicon Biosystems
16.3.7. Trovagene, Inc.
16.3.8. Guardant Health, Inc.
16.3.9. Mdxhealth SA
16.3.10. Genomic Health, Inc.
16.3.11. Raindance Technologies, Inc.
16.3.12. Thermo Fisher Scientific Inc.
16.3.13. Illumina, Inc.
17. Acronyms
Frequently Asked Questions
What is the projected market size & Compound Annual Growth Rate (CAGR) of the market?
The global liquid biopsy market in 2020 is estimated for more than US$ 1,013.6 Mn and expected to reach a value of US$ 2,563.9 Mn by 2028 with a significant CAGR of 12.3%.
What are the key factors driving the growth of market?
The growing prevalence of cancer among the population and substantial number of favorable trials of liquid biopsy are the key factors driving the growth of market
What segments are covered in market report?
The liquid biopsy market is segmented on the basis of circulating biomarker, cancer type, end user, product type, and by region.
What are the key participating players in the market?
Some of the key participating players in the liquid biopsy market are Biocept, Inc., Qiagen N.V., Roche Diagnostics, Bio-Rad Laboratories, Inc., Myriad Genetics, Inc., Menarini-Silicon Biosystems, Trovagene, Inc., Guardant Health, Inc., Mdxhealth SA, Genomic Health, Inc., Raindance Technologies, Inc., Thermo Fisher Scientific Inc., and Illumina, Inc.
